124I-Evuzamitide PET/CT Imaging In Patients With Lumbar Spinal Stenosis and Carpal Tunnel Syndrome

This clinical trial will use the amyloid-binding radiotracer, 124I-evuzamitide, to potentially detect amyloid, in the heart and elsewhere, in patients who have a history of lumbar spinal stenosis and/or carpal tunnel syndrome.

Inclusion Criteria: * Must be ≥ 60 years of age. * Must have given written informed consent (signed and dated) and any authorizations required by local law and be able to comply with all study requirements. * Must have a Congo red positive ligamentum flavum or tenosynovial specimen analysis after laminectomy or carpal tunnel release surgery that is visually categorized as either "extensive" amyloid load or "mild/moderate" amyloid load by an experienced reviewer. * Those with mild/moderate amyloid load in the connective tissue who also have a history of at least one other orthopedic clinical manifestation, including, but not limited to, carpal tunnel syndrome, lumbar spinal stenosis, trigger finger, biceps tendon rupture, and shoulder/hip/knee arthroplasty. * Females must be non-pregnant and non-lactating. Exclusion Criteria: * Subjects on dialysis. * Subjects with a confirmed diagnosis of systemic amyloidosis, other than musculoskeletal tissue. * Inability or unwillingness to comply with the study requirements. * Subjects taking heparin, or heparin derivatives (e.g. low molecular weight heparins) for anticoagulation. * Inability to lie still for \~40 minutes on the PET/CT scanner. * History of iodine (potassium iodide) allergy. * Other reason that would make the subject inappropriate for entry into this study.